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Abstract
Focal adhesion kinase (FAK) is an important mediator of extracellular matrix integrin signaling, cell motility, cell proliferation
and cell survival. Increased FAK expression is observed in a variety of solid human tumors and increased FAK expression and
activity frequently correlate with metastatic disease and poor prognosis. Herein we identify miR-7 as a direct regulator of
FAK expression. miR-7 expression is decreased in malignant versus normal breast tissue and its expression correlates
inversely with metastasis in human breast cancer patients. Forced expression of miR-7 produced increased E-CADHERIN and
decreased FIBRONECTIN and VIMENTIN expression in breast cancer cells. The levels of miR-7 expression was positively
correlated with E-CADHERIN mRNA and negatively correlated with VIMENTIN mRNA levels in breast cancer samples. Forced
expression of miR-7 in aggressive breast cancer cell lines suppressed tumor cell monolayer proliferation, anchorage
independent growth, three-dimensional growth in Matrigel, migration and invasion. Conversely, inhibition of miR-7 in the
HBL-100 mammary epithelial cell line promoted cell proliferation and anchorage independent growth. Rescue of FAK
expression reversed miR-7 suppression of migration and invasion. miR-7 also inhibited primary breast tumor development,
local invasion and metastatic colonization of breast cancer xenografts. Thus, miR-7 expression is decreased in metastatic
breast cancer, correlates with the level of epithelial differentiation of the tumor and inhibits metastatic progression.
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Introduction
miRNAs are a class of evolutionarily conserved, non-coding
single stranded RNAs (18–24 nucleotides) that inhibit gene
expression at the post-transcriptional level [1]. Mature miRNAs
operate via sequence specific interactions with the 39 untranslated
region (UTR) of cognate mRNA targets, causing degradation of
mRNAs and suppression of translation [2,3]. More than 60% of
human protein coding genes have been under selective pressure to
maintain pairing to miRNAs, suggesting that most mammalian
mRNAs are conserved targets of miRNAs [4]. In the past decade,
emerging evidences have demonstrated a central role for miRNAs
in the establishment and progression of human tumors. miRNAs
act as either oncogenes (e.g., miR-10b, miR-103/107 and miR-
30d) [5,6,7] or tumor suppressors (e.g., miR-31, miR-29 and miR-
200) [8,9,10].
Recently, miR-7 has been found to reduce EGFR (epidermal
growth factor receptor) expression in glioblastoma, breast and
prostate cancer cells [11,12]. miR-7 was also observed to reduce
the expression of several oncogenes including PAK1 (p21 activated
kinase 1) [13] and IGF-1R (insulin-like growth factor 1 receptor) in
breast cancer and tongue squamous cell carcinoma (TSCC) cell
lines respectively [14]. Furthermore, miR-7 was reported to be
down-regulated in glioblastoma and advanced TSCC [11,14].
However, only a rather limited amount of clinical specimens were
examined in these studies. Interestingly, Martens et al. (2008)
found that miR-7 and other three miRNAs were significantly
associated with aggressiveness of estrogen receptor positive (ER+)
primary breast tumors of patients with lymph node-negative
(LNN) disease [15], suggesting that miR-7 may be an oncomiR.
Therefore, there is a need to further delineate the expression and
function of miR-7 in breast cancer systematically.
Results
miR-7 is Down-regulated in Cancer Versus Normal Breast
and Inversely Correlated with Metastasis
In an attempt to understand the role of miR-7 during breast
cancer progression, we first determined the expression of miR-7 in
27 fresh specimens of normal breast tissues and 42 cases of breast
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cancer using quantitative reverse-transcription PCR. We observed
that miR-7 expression was significantly decreased in breast cancer
tissue compared with normal breast tissue (p,0.001, Fig. 1A). To
determine whether miR-7 is associated with breast cancer
metastasis, we further examined the miR-7 expression levels in
42 archived primary breast tumors. These tumors consisted of
primary tumors resected from 23 patients with lymph node
metastasis as well as tumors resected from 19 patients with no
detectable lymph node metastasis. qPCR analysis revealed that
patients who experienced metastasic relapse exhibited a markedly
lower miR-7 expression than in those without (p,0.001, Fig. 1B).
These results suggest that miR-7 may play an important role in
breast cancer progression and that decreased expression of miR-7
is associated with breast cancer metastasis.
FAK is a Direct Target of miR-7
To identify downstream targets of miR-7, we performed
bioinformatics analysis by use of three algorithms that predict
the mRNA targets of a particular miRNA – PicTar [16],
TargetScan [17], and miRanda [18]. FAK (PTK2) was one of
the putative target genes that were predicted by all three
algorithms (Fig. S1). FAK was of particular interest as its
expression has been observed to be upregulated and associated
with metastasis in several cancers including breast cancer [19].
Using RNAhybrid [20], we located two potential binding sites for
miR-7 at the 39UTR of FAK mRNA. These two sites were highly
conserved in several species (Fig. 2A). In an effort to determine
whether FAK is regulated by miR-7 through direct binding to its
39UTR, a series of 39UTR fragments including the full-length wild
type 39UTR, binding site 1 mutant and binding site 2 mutant
(Fig. 2B) were constructed and inserted into the psiCHECK2
luciferase reporter plasmid. The wild type and mutant vectors
were co-transfected with mature miR-7 and control miRNA in
MDA-MB-435s cells. miR-7 significantly decreased the luciferase
activity of wild type and binding site 2 mutant FAK 39UTR (more
than 50%) but not binding site 1 mutant FAK 39UTR. This
suggested that miR-7 interacts with the FAK mRNA 39UTR
through binding with the site 1 position because the activity of the
luciferase reporter that carries a binding site 1 mutant FAK
39UTR with substitution of four nucleotides within the miR-7
binding site was not reduced by miR-7 (Fig. 2C).
To assess the relationship between the endogenous levels of
FAK and miR-7, we next determined miR-7 expression and FAK
protein expression in a variety of breast cancer cell lines. FAK
protein levels were low in nonmalignant human mammary
epithelial HBL-100 cells and moderately invasive breast cancer
MDA-MB-468, MDA-MB-453 and MCF-7 cells but relatively
higher in highly invasive breast cancer MDA-MB-435s, MDA-
MB-231 and BT-549 cells. In contrast, miR-7 levels were
relatively high in HBL-100, MDA-MB-468, MDA-MB-453 and
MCF-7 cells and much lower in MDA-MB-435s, MDA-MB-231
and BT-549 cells (Fig. 2D). The T47D cell line is a moderately
invasive cell line but has a relatively low miR-7 and high FAK
expression, suggestive of alternate pathways to regulate miR-7 and
FAK expression in this cell line. In addition, immunoblot analyses
indicated that forced expression of miR-7 significantly reduced
endogenous FAK protein expression in both MDA-MB-435s and
MDA-MB-231 cells (Fig. 2E, Fig. S2A and S2B). Levels of
phosphorylated FAK (Tyr397), which is a critical event in integrin
mediated FAK signaling [21] was also decreased by forced
expression of miR-7 (Fig. 2E, S2A and S2B). Furthermore, after
transfection of miR-7 inhibitor in HBL-100 cell, the expression of
FAK and the levels of phospho-FAK (Tyr397) were dramatically
increased (Fig. 2E and Fig. S2C). These results indicate that miR-7
expression is inversely correlated with FAK expression and
activation in breast cancer cell lines and that miR-7 directly
regulates FAK expression.
miR-7 Determines Epithelial Phenotype of Breast Cancer
Cells
We noticed that forced expression of miR-7 promoted striking
change in the morphology of MDA-MB-435s and MDA-MB-231
cells, whereby the spindle-, fibroblast-like morphology switched to
the cobblestone-like appearance of epithelial cells (Fig. 3A). The
altered cell morphology produced by forced expression of miR-7
was also quantified by measuring dendricity/inverse shape factor
(Fig. S2D). These morphological changes are hallmarks of reduced
epithelial-to-mesenchymal transition (EMT). To determine if the
Figure 1. miR-7 expression is decreased in breast cancer and is associated with tumor metastasis. (A) The expression level of mature
miR-7 in breast cancer (n = 42) or normal breast tissues (n = 27) was determined using quantitative PCR. Both breast cancer and normal breast are
fresh tissues. Box-plot lines represent medians and interquartile ranges of the normalized threshold values; whiskers and spots indicate 10–90
percentiles and the remaining data points. (B) The relative expression of mature miR-7 in 19 non-metastatic breast cancer tissue and 23 metastatic
breast cancer tissue samples. The expression level of mature miR-7 is normalized to U6 small nuclear RNA.
doi:10.1371/journal.pone.0041523.g001
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Figure 2. miR-7 decreases FAK expression by directly targeting its 39-UTR. (A) The potential binding sequences for miR-7 within the FAK 39-
UTR of human (H.s), chimpanzee (P.t), mouse (M.m), guinea pig (C.p), rabbit (O.c), rat (R.n), and dog (C.f). Seed sequences are highlighted and
underlined. (B) Luciferase reporter plasmids were constructed by the insertion of full length FAK 39-UTR into the region immediately downstream of
the luciferase gene. The sequences of two predicted miR-7 binding sites within the FAK 39-UTR, including wild-type full-length UTR or mutant
miR-7 Inhibits EMT and Metastasis via FAK
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molecular changes typical of a reduced EMT occurred in miR-7
expressing cells, we examined the expression of mesenchymal
markers, such as FIBRONECTIN, VIMENTIN, N-CADHERIN,
SNAIL and the epithelial marker E-CADHERIN in MDA-MB-
435s and MDA-MB-231 cells. Immunoblot analysis showed that
expression of both FIBRONECTIN, VIMENTIN and SNAIL
were decreased in MDA-MB-435s and MDA-MB-231 cells with
forced expression of miR-7 (Fig. 3B). The protein level of N-
CADHERIN was also decreased in MDA-MB-435s cells with
forced expression of miR-7. N-CADHERIN protein expression
was not detectable by immunoblot analysis in MDA-MB-231 cells
(Fig. 3B). Furthermore, forced expression of miR-7 increased
expression of E-CADHERIN in both cell lines whereas the control
transfected cells remained E-CADHERIN negative (Fig. 3B).
To determine whether the expression of E-CADHERIN
correlated to miR-7 levels in breast cancer, we quantified miR-7
as well as E-CADHERIN mRNA expression in a cohort of breast
cancer samples. From the cohort of 42 primary breast cancer, we
observed a significant positive correlation between E-CADHERIN
mRNA and miR-7 miRNA expression (Fig. 3D). We also analyzed
the expression of miR-7 versus the expression of VIMENTIN
mRNA in this cohort. We observed a significant inverse
correlation between miR-7 miRNA and VIMENTIN mRNA
expression in patient tumors (Fig. 3E). This data suggested a strong
association between miR-7 expression and markers of epithelial
differentiation.
miR-7 Impairs Breast Cancer Cell Migration and Invasion
in vitro
Given that the expression of miR-7 was inversely correlated
with metastasis of breast cancer, we considered whether miR-7
might possess an important role in breast cancer cell migration
and invasion. Transwell migration and Matrigel invasion assays
demonstrated that miR-7 significantly reduced the migration and
invasion capacity of MDA-MB-435s and MDA-MB-231 cells
(Fig. 4A). As FAK is frequently up-regulated in breast cancer and
promotes cell migration and invasion, and as miR-7 can directly
regulate the expression of FAK, we next ascertained whether
reduction of FAK expression might provide an explanation for the
reduction of cell migration and invasion observed following forced
expression of miR-7. We therefore forced the expression of miR-7
in MDA-MB-435s and MDA-MB-231 cells together with a
construct containing the FAK coding sequence but lacking the
39UTR of the FAK-encoding mRNA; and as such, this construct
yielded a FAK mRNA that is resistant to miR-7. The restoration
of FAK expression was confirmed through immunoblot analysis
(Fig. 4C). Transwell assays indicated that restoration of FAK
expression significantly abrogated miR-7 reduced cell migration
and invasiveness (Fig. 4B), indicative that FAK is both a direct and
functional target for miR-7.
miR-7 Inhibits Breast Cancer Cell Growth in vitro
To determine the function of miR-7 in the progression of breast
cancer, we sought to determine whether miR-7 may also affect the
proliferation of breast cancer cells. The proliferation rates of
MDA-MB-435s and MDA-MB-231 cells transfected with mature
miR-7 were significantly decreased when compared with those of
control miRNA transfected cells (Fig. 5A). We subsequently
utilized HBL-100 cells, which possess high relative expression of
miR-7 to further determine the functional effects of inhibition of
miR-7. Transfection of miR-7 inhibitor increased cell proliferation
in HBL-100 cells (Fig. 5A). Furthermore, transfection of miR-7
mimics in MDA-MB-435s cells produced a significant decrease in
colony formation in soft agar compared with control mimics
(Fig. 5B). Conversely, silencing of miR-7 in HBL-100 cells
increased colony formation in soft agar (Fig. 5C). These results
indicated that miR-7 inhibits breast cancer cells monolayer
proliferation and anchorage independent growth in vitro.
We also cultured the cells in three-dimensional Matrigel [22];
growing cells in or on gels which revealed cellular behavior that
are more relevant to EMT and metastasis. Less colony formation
was observed for miR-7 transfected MDA-MB-435s and MDA-
MB-231 cells compared to control transfected cells (Fig. 5D).
Moreover, the colonies formed by control transfected cells in 3D
Matrigel were larger and the cells in those colonies appeared more
motile and invasive compared with colonies formed by miR-7
transfected cells (Fig. 5D). miR-7 expressing cells produced
circumscribed colonies, whereas a large number of control
transfected cells spread from the main bulk of the colony
(Fig. 5D), suggesting that miR-7 inhibited invasive cellular
behavior.
miR-7 Decreases Tumor Growth and Suppresses
Metastasis in vivo
To determine whether miR-7 regulates tumor growth and
metastasis in vivo, we utilized xenograft models by injection of
MDA-MB-435s cells, with forced expression of miR-7, orthotop-
ically in the mammary fat pad of nude mice. Forced expression of
miR-7 decreased primary tumor growth by 1.5-fold and corre-
spondingly decreased cell proliferation as determined by immu-
nohistochemical analysis of nuclear incorporation of BrdU (Fig. 6A
and D) and increased cell apoptosis as determined by TUNEL
assay (Fig. 6 D). The tumor xenografts derived from cells with
forced expression of miR-7 exhibited lower expression of FAK,
FIBRONECTIN and VIMENTIN than control tumors (Fig. 6C).
Strikingly, a significant number of miR-7 expressing carcinoma
cells exhibited staining for human E-CADHERIN (Fig. 6C). The
control tumors were essentially E-CADHERIN negative (Fig. 6C).
The relative expression of FAK, FIBRONECTIN and VIMEN-
TIN between miR-7 expressing tumors and control tumors were
also analyzed by quantifying DAB staining intensity (Fig. S2E).
Control primary tumors displayed evidence of local invasion
(Fig. 6B); however, tumors with forced expression of miR-7 were
well encapsulated and non-invasive (Fig. 6B). Not only did cells
with forced expression of miR-7 generate smaller primary tumors,
but miR-7 also strikingly impaired in their capacity to seed lung
metastasis. Cells with forced expression of miR-7 produced no
metastatic lesions in contrast to control cells that formed lesions in
the lungs in 2 of 6 mice with tumors orthotopically implanted
(Fig. 6B).
We also determined the effect of miR-7 on metastasis was also
attributable to effects on later steps of the invasion-metastasis
cascade, independent of miR-7 influence on cellular invasion.
Thus, we injected MDA-MB-435s cells with forced expression of
(highlighted and underlined) binding site are shown. (C) Relative luciferase activity was analyzed after the above reporter plasmids or control reporter
plasmid were cotransfected with miR-7 mimics or control mimics in MDA-MB-435s cells. (D) Relative expression of miR-7 by quantitative PCR (top)
and immunoblot for FAK expression (bottom) in the indicated cell lines. NT, non-tumorigenic. (E) Immunoblot assays of endogenous FAK protein
levels in MDA-MB-435s and MDA-MB-231 cells transfected with miR-7 mimics or control mimics and those in HBL-100 cells transfected with miR-7
inhibitor or control inhibitor.
doi:10.1371/journal.pone.0041523.g002
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miR-7 into the venous circulation of mice. After 30 days, MDA-
MB-435s cells with forced expression of miR-7 generated fewer
lung metastases than did control (Fig. 7A and B). Quantification of
human HPRT mRNA also demonstrated that miR-7 decreased
the number of metastatic cancer cells in the mouse lungs (Fig. 7C).
Figure 3. miR-7 promotes an epithelial phenotype in breast cancer cells. (A) Morphology of MDA-MB-435s and MDA-MB-231 cells
transiently transfected with mature miR-7 or the control miRNA. (B) Immunoblot analysis of FIBRONECTIN, VIMENTIN, E-CADHERIN, N-CADHERIN and
SNAIL in MDA-MB-435s and MDA-MB-231 cells transfected with mature miR-7 or control miRNA. (C) The correlation of mature miR-7 with E-CADHERIN
mRNA in 42 breast cancer samples. (D) Correlation of mature miR-7 with VIMENTIN mRNA in 42 breast cancer samples. Pearson correlation
coefficients (R) and P-values (p) are indicated.
doi:10.1371/journal.pone.0041523.g003
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Discussion
MicroRNAs are increasingly implicated in regulating the
malignant progression of cancer by directly targeting oncogenes
and tumor suppressor genes. Each miRNA can potentially interact
with several mRNA targets via perfect or imperfect base pairing,
primarily in the 39-UTR portion. A number of target prediction
algorithms, including TargetScan, PicTar and miRanda, relying
on seed sequence pairing rules and conservational analysis, have
been developed to score possible recognition sites and identify
putative gene targets. However, these predictions usually yield a
large number of false-positive candidates and experimental
validation is thus strictly required [23]. In the present study, we
located two potential binding sites (site 1 and site 2) of miR-7 in the
FAK 39UTR with RNAhybrid (Fig. 2A). However, only binding
site 2 was predicted by three algorithms (PicTar, TargetScan and
miRanda). Luciferase reporter assays with mutant binding site 1
and binding site 2 of FAK 39UTR revealed that miR-7 interacts
with FAK 39UTR was through binding with site 1 (Fig. 2C), thus
confirming the importance of experimental validation.
It is likely that some changes in cell adhesion occur at focal
adhesion plaques which are cell/extracellular matrix (ECM)
contact points containing integrin receptors, cytoskeletal compo-
nents and intracellular signalling proteins such as focal adhesion
Figure 4. Restoration of FAK attenuates miR-7 mediated cell migration and invasion inhibition. (A) Transwell migration and invasion
assays of MDA-MB-435s and MDA-MB-231 cells transfected with miR-7 mimics and control mimics. (B) Transwell migration and invasion assays of
MDA-MB-435s and MDA-MB-231 cells transfected with miR-7 mimics and control mimics with or without FAK restoration. (C) Immunoblot analysis of
FAK expression in MDA-MB-435s and MDA-MB-231 cells transfected with miR-7 mimics or control mimics with or without FAK restoration. ** p,0.01,
*** p,0.001.
doi:10.1371/journal.pone.0041523.g004
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Figure 5. miR-7 inhibits breast cancer cell tumorigenesis in vitro. (A) miR-7 decreases MDA-MB-435s and MDA-MB-231 cell proliferation in
vitro and inhibition of endogenous miR-7 expression promotes HBL-100 cell monolayer proliferation. (B) miR-7 inhibits MDA-MB-435s anchorage
independent growth in soft agar. (C) Inhibition of miR-7 promotes HBL-100 cell anchorage independent growth in soft agar. (D) Morphology of MDA-
MB-435s and MDA-MB-231 cells cultured in three-dimensional Matrigel after transfection with mature miR-7 or the control miRNA.
doi:10.1371/journal.pone.0041523.g005
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kinase (p125FAK) [24,25]. FAK also performs protein-protein-
interaction adaptor functions at sites of cell attachment to the
ECM, thereby contributing to focal-adhesion ‘scaffolding’, and
transmits adhesion-dependent and growth factor-dependent sig-
nals into the cell interior [26]. In tumor cells, FAK is thought to
possess a dual function, both in promoting tumor cell adhesion
and in acting as a survival signal to inhibit apoptosis as the tumor
develops the anchorage independent growth capacity [27]. Many
studies, which are mainly based on immunohistochemical and
immunoblotting analysis, have demonstrated that FAK expression
Figure 6. miR-7 inhibits breast cancer cell growth, local invasion in vivo. (A) Primary tumor growth upon orthotopic injection of 1.06106
MDA-MB-435s cells infected as indicated. n = 12 per group per time point. (B) H&E staining of primary tumors and mice lungs after orthotopic
injection. Arrows: tumor cells venous (a), muscle (b) invasion and lung metastasis foci (d). (scale bar: 100 mm) (C) FAK, VIMENTIN, FIBRONECTIN, E-
CADHERIN stained primary tumors after orthotopic injection. Arrow indicate metastatic foci (scale bar: 50 mm). (D) Evaluation of nuclear BrdU
incorporation and TUNEL positive (apoptotic) nuclei in MDA-MB-435s tumors. ***, p,0.001.
doi:10.1371/journal.pone.0041523.g006
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is increased in cancers of the thyroid, prostate, cervix, colon,
rectum, oral epithelium, ovary and breast [28–36]. In breast,
increased expression of FAK in benign and malignant tissues is
correlated with preinvasive and invasive phenotype and high FAK
expression in invasive breast carcinoma is associated with an
aggressive phenotype [34,37].
The molecular mechanisms responsible for the increased FAK
expression in breast cancer remain largely unknown but miR-7
may represent one mechanism. In addition to breast cancer, FAK
gene amplification increased has been observed in head and neck
cancer [38]. A recent report identified binding sites for the p53
tumor suppressor and NF-kB in the FAK promoter. These studies
showed that p53 and NF-kB binding was able to suppress or
activate expression of FAK respectively, suggesting aberrant
expression or mutation of p53 and/or NF-kB could play a role
in increased FAK expression in breast cancer [39]. However, we
have described herein that altered posttranscriptional control of
FAK mRNA by miRNAs may also contribute to increased FAK
expression during breast cancer progression.
Complications from metastatic disease are the primary cause of
death in breast cancer. The metastasis process depends on tumor
cell intravasation, adhesion to the vessel wall, extravasation,
infiltration, and proliferation into target tissue [40]. Many of these
steps involve integrins, a family of transmembrane adhesion
receptors composed of noncovalently linked a and b subunits [41].
Several miRNAs have reported to control cancer cell metastasis
through target integrin and integrin related adhesion molecular.
Valastyan et al. (2010) reported that miR-31 inhibits breast cancer
metastasis via the pleiotropic suppression of a cohort of
prometastatic target genes that include integrin a5 (ITGA5)
[42]. Integrin b3 expression is also regulated by let-7a miRNA in
malignant melanoma [43]. Integrins can alter cellular behavior
through the recruitment and activation of signaling proteins such
as non-receptor tyrosine kinases including FAK and c-Src that
form a dual kinase complex [44]. Recently, Ding et al. (2010)
demonstrated that miR-151 is frequently expressed together with
its host gene FAK and can function synergistically with FAK to
enhance hepatocellular carcinoma cells motility and spreading
[45].
A proposed critical step in the conversion of primary tumors to
metastases is attributed to the process known as epithelial-to-
mesenchymal transition (EMT). EMT is a remarkable example of
cellular plasticity that involves the dissolution of epithelial tight
junctions, the intonation of adherens junctions, the remodeling of
the cytoskeleton, and the loss of apical-basal polarity [46,47]. Our
data reveals that miR-7 inhibits EMT which promotes the
conversion of highly invasive breast cancer cells with mesenchymal
characteristic to the cells with epithelial properties. Transforming
growth factor-b (TGF-b) has emerged as a key regulator of EMT
in late-stage carcinomas, where it promotes invasion and
metastasis [48]. Cicchini et al. (2007) have demostrated that
FAK is required for the TGF-b induced EMT in hepatocytes [49].
Figure 7. miR-7 inhibits breast cancer cell metastasis to mice lungs. (A) H&E stained sections of lungs isolated from mice that received tail
vein injection of miR-7 or control infected MDA-MB-435s cells (scale bar: 100 mm). (B) Numbers of lung micrometastases per section in individual mice
(each data point represents a different mouse; n = 7 mice per group). (C) Expression of human HPRT mRNA relative to mouse 18S rRNA in the lungs of
the tumor-bearing mice.
doi:10.1371/journal.pone.0041523.g007
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Thus, FAK is an important regulatory element in the process of
EMT. miR-7 has also been reported to target PAK1 in breast
cancer cells [13]. PAK1 phosphorylates and modulates the
subcellular localization of snail in BC cells and subsequent EMT
[50]. miR-7 may therefore co-ordinately regulate breast cancer
cells EMT.
Analysis of miR-7 as well as E-CADHERIN and VIMENTIN
mRNA levels in breast cancer tissues reveals that miR-7 expression
is an indicator of epithelial differentiation in breast cancer. Recent
studies have also identified the miR-200 family as a powerful
marker and determining factor of the epithelial phenotype of
cancer cells by targeting the E-CADHERIN repressors ZEB1 and
ZEB2 [10,51].
While we were preparing the manuscript, it was reported that
miR-7 regulated cancer cell invasion by targeting FAK expression
in glioblastoma [52]. In that report, miR-7 levels in glioma tissues
are inverse correlated with FAK expression when combined with
work herein in breast cancer, it appears that miR-7 is a conserved
miRNA that inhibits the same target gene and plays similar
functions in several tumor types.
Materials and Methods
Tissue Samples
All patients signed informed consent approving the use of their
tissues for research purposes and the study was approved by the
Institutional Review Board of the Anhui Medical University. Fresh
tissues including 42 breast cancer and 27 normal breast samples
derived from 69 patients that underwent surgery at the First
Affiliated Hospital of Anhui Medical University between 2009 and
2010 were used for the study. All tissue samples were H&E stained
and had been reviewed by two independent pathologists in Anhui
Medical University.
Cell Lines
HBL-100, MCF-7, T47D, MDA-MB-468, MDA-MB-453,
MDA-MB-231, MDA-MB-435s, BT-549 and HEK293T cell lines
were from ATCC and cultured as recommended.
Constructs
The human FAK cDNA expression plasmid pKH3-FAK was
kind gift from Dr. Junlin Guan (University of Michigan). The
ORF region of FAK cDNA was subcloned into pIRES neo3
plasmid. The 39 untranslated region (39-UTR) sequence of FAK
was amplified from the genomic DNA of normal breast tissues and
subcloned into the psiCHECK2 dual luciferase reporter plasmid
(Promega). The mutant construct of FAK 39UTR was generated
using a QuikChange Site-Directed Mutagenesis Kit (Stratagene).
RNA Isolation, miRNA and mRNA Detection
Total RNA, inclusive of the small RNA fraction, was extracted
from cultured cells and clinical samples with a mirVana miRNA
Isolation Kit (Ambion). Mature miR-7 was reverse-transcribed
with specific RT primers, quantified with a TaqMan probe, and
normalized by U6 small nuclear RNA using TaqMan miRNA
assays (Applied Biosystems). mRNA expression analysis was
conducted by quantitative PCR using SYBR green dye, with
relative changes calculated by the DDCt method.
miRNA Gene Cloning and Ectopic Expression
The human miR-7 gene was PCR-amplified from normal
genomic DNA and cloned into the pBabe-puro retroviral vector.
The pBabe-amphotrophic viruses were generated by cotransfec-
tion of HEK293T cells with the pBabe constructs, pCMV-VSVG
and Gag/Pol using Attractene Transfection Reagent (Qiagen).
Virus was harvested at 48 and 72 h posttransfection and infections
were performed in the presence of 8 mg/mL of polybrene
(SigmaAldrich). Following transduction, cells were selected with
1 mg/mL puromycin (SigmaAldrich).
Primers
Primers used were as follows: FAK ORF (GCGCGGCTAG-
CATGGCAGCTGCTTACCTTGACCCCA,
ATAGCGGCCGCTCAGTGTGGTCTCGTCTGCCCAAGC);
miR-7 ectopic expression (AGGATCCTACAGGAACACAG-
GACCAGA, CCGAATTCTGATAAACACGTCCATTACA),
FAK 39UTR cloning (ATCTCGAGGCCTCCCCTAGGAG-
CACGTCTT, GCGCGGCCGCTTTACTGGTAA-
CACCTTTTTAAT), E-CADHERIN, VIMENTIN and





the in vivo xenograft, the following primers were used:
hHPRT(TTCCTTGGTCAGGCAGTATAATCC,
AGTCTGGCTTATATCCAACACTTCG); mouse 18s rRNA(-
GAAACGGCTACCACATCC, ACCAGACTTGCCCTCCA).
Oligonucleotide and Plasmid Transfection
miRNA mimics (Genepharma, Shanghai, China) and miScript
miRNA inhibitor (Qiagen) were transfected using HiPerFect
Transfection Reagent (Qiagen) following the manufacturer’s
instructions. miRNA mimics and plasmid co-transfection were
performed by using Lipofectamine 2000 (Invitrogen). Twenty-four
hours after transfection, cells were plated for proliferation, soft
agar, migration, invasion assays or harvested for the luciferase
reporter assay. Cells were harvested for RNA and protein analyses
at forty-eight hours after transfection.
In vitro Migration and Invasion Assay
For transwell migration assays, 106104 cells were plated in the
top chamber with the non-coated membrane (24-well insert; 8 mm
pore size; BD Biosciences). For invasion assays, 26105 cells were
plated in the top chamber with Matrigel-coated membrane (24-
well insert; 8 mm pore size; BD Biosciences). In both assays, cells
were plated in medium without serum, and medium supplemented
with 10% serum was used as a chemoattractant in the lower
chamber. The cells were incubated for 24 to 36 hours and cells
that did not migrate or invade through the pores were removed by
a cotton swab. Filters were fixed with 90% ethanol, stained by
0.1% crystal violet, photographed and cells numbers were
counted.
Cell Proliferation and Soft Agar Colony Formation Assays
Cell proliferation was determined by Cell Counting Kit-8
(Dojindo, Shanghai, China) according to the manufacturer’s
instructions. For soft agar colony formation assay, cells (56103)
in 1.5 mL medium supplemented with 0.35% agarose were
layered on a 1.5 mL base medium with 0.5% agarose. Soft agar
assays were performed in six well plates and in triplicate. Cells
were cultured for 14 days and colonies were counted.
Three-dimensional Matrigel Culture
Eight hundred cells per well were plated in 10% FBS medium
supplemented with 4% Matrigel (BD Bioscience) in a 96-well plate
which coated with Matrigel before addition of the cells. Matrigel-
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containing (4%) medium was renewed every 3 d until the
experiment was terminated after 10 d.
Orthotopic Injection
The animals were maintained in a pathogen-free barrier facility
at the Aninal Center of the University of Science and Technology
of China (USTC), and closely monitored by animal facility staff.
All animal work procedures were approved by USTC Ethics
Committee for Animal Care and Use (Protocol number :UST-
CACUC1201040) and were performed in accordance with the
regulations of animal care of USTC and conformed to the legal
mandates and national guidelines for the care and maintenance of
laboratory animals.
MDA-MB-435s cells (26106 cells in 100 mL PBS) were injected
orthotopically into the each side mammary fat pad of female
BALB/c-nu/nu mice (Slaccas, Shanghai, China). Each group
consisted of six mice. Tumor growth rates were analyzed by
measuring tumor length (L) and width (W), and calculating volume
through the use of the formula LW2/2. Six hours before sacrifice,
mice were i.p injected BrdU solution at the 100 mg/g body weight.
Tail Vein Injection
MDA-MB-435s cells (16106 cells in 200 mL PBS) were injected
directly into the lateral tail vein of 6- to 8-week-old female BALB/
c-nu/nu mice. Each group consisted of eight mice. Mice were
sacrificed on day 35 (orthotopic injection) or day 30 (tail vein
injection) and mammary tumors, mice liver and lung were fixed in
10% neutral buffered formalin and embedded in paraffin for
histology examination or were frozen at 280uC in RNALater
(Ambion) for RNA extraction and qPCR analysis.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was cut into 5 mm
section, de-paraffinized in xylene, rehydrated through graded
ethanol, quenched for endogenous peroxidase activity in 3% (v/v)
hydrogen peroxide, and processed for antigen retrieval by heating
in 10 mM citrate buffer (pH 6.0) at 90–100uC (FAK, VIMEN-
TIN, FIBRONECTIN, E-CADHERIN) or digesting with 0.1%
trypsin at 37uC (BrdU). Sections were incubated at 4uC overnight
with FAK (3258, 1:200, Cell Signaling Technology), VIMENTIN
(550513, 1:200, BD Pharmingen), FIBRONECTIN (610077,
1:200, BD Transduction Laboratories), E-CADHERIN (610181,
1:200, BD Transduction Laboratories) or BrdU (MAB0188, 1:100,
Maixin, Fuzhou, China ) antibody. Immunostaining was per-
formed using UltraSensitive S-P Detection Kit (KIT-9720,
Maixin, Fuzhou, China), and then color was developed by using
a DAB kit (DAB-0031, Maixin, Fuzhou, China). Subsequently,
sections were counterstained with hematoxylin. TUNEL assay was
performed with an in situ cell death detection kit (Roche)
according to the manufacturer’s instructions.Quantification of
immunohistochemical stain intensity was performed as previously
described [53].
Luciferase Reporter Assay
Luciferase reporter assays were performed using the psi-
CHECK2-FAK-39-UTR vector. Cells were grown to approxi-
mately 60% confluence in 24-well plates and cotransfected with
psiCHECK2-FAK-39-UTR (wild type or mutant) or psiCHECK2
empty vector plus miR-7 mimics or control mimics using
Lipofectamine 2000 (Invitrogen). After 24 hours of incubation,
Firefly and Renilla luciferase activities were evaluated using the
Dual-Luciferase Reporter Assay system (Promega).
Immunoblot
Cells were extracted in modified RIPA lysis buffer
(150 mM NaCl, 50 mM Tris, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 1 mM EDTA, protease inhibitor cocktail (Roche)).
Proteins from total cell lysates were resolved by SDS-PAGE,
transferred to the Nitrocellulose membrane (GE healthcare),
blocked in 5% non-fat milk in PBS/Tween-20, and blotted with
the antibodies for FAK (3258, 1:1000, Cell Signaling Technology),
phospho-FAK(Tyr397) (3283, 1:1000, Cell Signaling Technology),
VIMENTIN (550513, 1:5000, BD Pharmingen), FIBRONECTIN
(610077, 1:5000, BD Transduction Laboratories), E-CADHERIN
(610181, 1:5000, BD Transduction Laboratories), N-CADHERIN
(610920, 1:2000, BD Transduction Laboratories), SNAIL (sc-
28199, 1:1000, SantaCruz Biotechnology) and GAPDH (M20028,
1:5000, Abmart, Shanghai, China).
Measuring Dendricity
Measuring cell dendricity was performed as previously de-
scribed [54].
Statistical Analysis
Data are presented as mean 6 SD (standard deviation).
Student’s t test (two tailed) was used to compare two groups,
p,0.05 was considered significant.
Supporting Information
Figure S1 miR-7 target genes that predicted by all
theree algorithms. (A) Schematic illustration of target genes by
three algorithms respectively. (B) 114 target genes of miR-7 that
can be predicted by all three algorithms.
(TIF)
Figure S2 Quantification of immunoblot bands intens-
tity and IHC DAB staining intensity. (A) Quantification of
immunoblot FAK and p-FAK bands intensity relative to GAPDH
intensity in MDA-MB-435s cells are shown. (B) Quantification of
immunoblot FAK and p-FAK band intensity relative to GAPDH
intensity in MDA-MB-231 cells are shown. (C) Quantification of
immunoblot FAK and p-FAK band intensity relative to GAPDH
intensity in HBL-100 cells are shown. (D) Quantification of
dendricty/inverse shape factor in MDA-MB-435s and MDA-MB-
231 cells. (E) Quantification of relative DAB staining intensity in
MDA-MB-435s derived tumor sections are shown.
(TIF)
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